PMID- 34019468
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 17
IP  - 8
DP  - 2021 Aug 3
TI  - Sequential administration of Prevnar 13 and PNEUMOVAX 23 in healthy 
      participants 50 years of age and older.
PG  - 2678-2690
LID - 10.1080/21645515.2021.1888621 [doi]
AB  - In most countries worldwide, pneumococcal conjugate vaccines have been included 
      in the infant immunization program, resulting in a significant reduction in the 
      burden of pneumococcal disease in children and adults. Shifting serotype 
      distribution due to the indirect effect of infant vaccination with the 13-valent 
      pneumococcal conjugate vaccine (PCV13) may continue to increase the gap between 
      23-valent pneumococcal polysaccharide vaccine (PPSV23) and PCV13 serotype 
      coverage for older adults in the coming years. This clinical study (V110-029; 
      NCT02225587) evaluated the safety and immunogenicity of sequential administration 
      of PCV13 followed approximately 8 weeks later, or approximately 26 weeks later, 
      by PPSV23 in healthy adults >/=50 years of age. Both dosing intervals were 
      generally well tolerated as measured by the nature, frequency, and intensity of 
      reported adverse events (AEs) in both vaccination groups. Serotype-specific 
      opsonophagocytic activity (OPA) geometric mean titers (GMTs) measured 30 days 
      following receipt of PPSV23 in either group and at Week 30 were generally 
      comparable between the 2 groups for 6 serotypes unique to PPSV23 and 12 serotypes 
      shared between PCV13 and PPSV23, regardless of the interval between receipt of 
      PCV13 and PPSV23. In addition, administration of PPSV23 given either 8 weeks or 
      26 weeks following PCV13 did not negatively impact immune responses induced by 
      PCV13. Furthermore, administration of PPSV23 given either 8 weeks or 26 weeks 
      after PCV13 elicited serotype-specific OPA GMTs to serotypes unique to PPSV23, 
      which could provide earlier protection against pneumococcal disease caused by 
      these serotypes in comparison with the current Advisory Committee on Immunization 
      Practices recommended interval of at least 12 months.
FAU - Buchwald, Ulrike K
AU  - Buchwald UK
AUID- ORCID: 0000-0002-6671-0115
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Andrews, Charles P
AU  - Andrews CP
AD  - Diagnostics Research Group, San Antonio, TX, USA.
FAU - Ervin, John
AU  - Ervin J
AD  - Alliance for Multispecialty Research, Knoxville, TN, USA.
FAU - Peterson, James T
AU  - Peterson JT
AD  - Foothill Family Clinic, Salt Lake City, UT, USA.
FAU - Tamms, Gretchen M
AU  - Tamms GM
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Krupa, David
AU  - Krupa D
AD  - IQVIA, Durham, NC, USA.
FAU - Ajiboye, Patrick
AU  - Ajiboye P
AD  - IQVIA, Durham, NC, USA.
FAU - Roalfe, Lucy
AU  - Roalfe L
AD  - University College London, London, UK.
FAU - Krick, Andrea L
AU  - Krick AL
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Sterling, Tina M
AU  - Sterling TM
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Wang, Meihua
AU  - Wang M
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Martin, Jason C
AU  - Martin JC
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Stek, Jon E
AU  - Stek JE
AUID- ORCID: 0000-0001-7521-874X
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Kohn, Melvin A
AU  - Kohn MA
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Folaranmi, Temitope
AU  - Folaranmi T
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Abeygunawardana, Chitrananda
AU  - Abeygunawardana C
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Hartzel, Jonathan
AU  - Hartzel J
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Musey, Luwy K
AU  - Musey LK
AUID- ORCID: 0000-0001-5484-7037
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
CN  - V110-029 Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT02225587
SI  - EudraCT/2013-003027-11
PT  - Journal Article
DEP - 20210521
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Heptavalent Pneumococcal Conjugate Vaccine)
RN  - 0 (Pneumococcal Vaccines)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
MH  - Aged
MH  - Antibodies, Bacterial
MH  - Child
MH  - Double-Blind Method
MH  - Healthy Volunteers
MH  - Heptavalent Pneumococcal Conjugate Vaccine
MH  - Humans
MH  - *Pneumococcal Infections/prevention & control
MH  - Pneumococcal Vaccines
MH  - *Streptococcus pneumoniae
MH  - Vaccines, Conjugate/adverse effects
PMC - PMC8475587
OTO - NOTNLM
OT  - Pneumococcal vaccine
OT  - immunogenicity
OT  - safety
OT  - sequential administration
EDAT- 2021/05/22 06:00
MHDA- 2021/10/14 06:00
PMCR- 2021/05/21
CRDT- 2021/05/21 17:12
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2021/05/21 17:12 [entrez]
PHST- 2021/05/21 00:00 [pmc-release]
AID - 1888621 [pii]
AID - 10.1080/21645515.2021.1888621 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2021 Aug 3;17(8):2678-2690. doi: 
      10.1080/21645515.2021.1888621. Epub 2021 May 21.